ATE265857T1 - Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie - Google Patents

Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie

Info

Publication number
ATE265857T1
ATE265857T1 AT00935478T AT00935478T ATE265857T1 AT E265857 T1 ATE265857 T1 AT E265857T1 AT 00935478 T AT00935478 T AT 00935478T AT 00935478 T AT00935478 T AT 00935478T AT E265857 T1 ATE265857 T1 AT E265857T1
Authority
AT
Austria
Prior art keywords
hyperoxaluria
pharmaceutical
prevention
treatment
dietetic composition
Prior art date
Application number
AT00935478T
Other languages
English (en)
Inventor
Simone Claudio De
Original Assignee
Actial Farmaceutica Lda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actial Farmaceutica Lda filed Critical Actial Farmaceutica Lda
Application granted granted Critical
Publication of ATE265857T1 publication Critical patent/ATE265857T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
AT00935478T 1999-05-28 2000-05-24 Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie ATE265857T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000338A IT1309427B1 (it) 1999-05-28 1999-05-28 Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
PCT/IT2000/000213 WO2000072855A2 (en) 1999-05-28 2000-05-24 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria

Publications (1)

Publication Number Publication Date
ATE265857T1 true ATE265857T1 (de) 2004-05-15

Family

ID=11406789

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935478T ATE265857T1 (de) 1999-05-28 2000-05-24 Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie

Country Status (34)

Country Link
US (2) US6562336B2 (de)
EP (1) EP1181027B1 (de)
JP (1) JP4737836B2 (de)
KR (1) KR100781703B1 (de)
CN (1) CN100350919C (de)
AR (1) AR024555A1 (de)
AT (1) ATE265857T1 (de)
AU (1) AU773459B2 (de)
BR (1) BR0011038B1 (de)
CA (1) CA2373255C (de)
CZ (1) CZ20014076A3 (de)
DE (1) DE60010456T2 (de)
DK (1) DK1181027T3 (de)
DZ (1) DZ3165A1 (de)
EA (1) EA004257B1 (de)
EE (1) EE200100618A (de)
ES (1) ES2219344T3 (de)
HK (1) HK1048066B (de)
HU (1) HU225134B1 (de)
IL (3) IL146703A0 (de)
IS (1) IS6150A (de)
IT (1) IT1309427B1 (de)
MA (1) MA26790A1 (de)
MX (1) MXPA01012184A (de)
NO (1) NO20015782L (de)
NZ (1) NZ516020A (de)
PL (1) PL352014A1 (de)
PT (1) PT1181027E (de)
SI (1) SI1181027T1 (de)
SK (1) SK16612001A3 (de)
TR (1) TR200103439T2 (de)
UA (1) UA71621C2 (de)
WO (1) WO2000072855A2 (de)
ZA (1) ZA200110504B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US8697051B2 (en) * 1999-06-09 2014-04-15 Vsl Pharmaceuticals Inc. Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
ITRM20010763A1 (it) * 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
US9655932B2 (en) 2002-03-13 2017-05-23 Kibow Biotech, Inc. Composition and method for preventing or treating gout or hyperuricemia
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
US11103542B2 (en) 2002-03-13 2021-08-31 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
CN1812801A (zh) * 2003-06-24 2006-08-02 大塚制药株式会社 降低血清尿酸水平的组合物
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
WO2005089564A1 (en) 2004-03-19 2005-09-29 Danisco A/S Emulsifier composition for shortening
EP1814995A2 (de) * 2004-10-27 2007-08-08 North Carolina State University Nukleinsäuren aus lactobacillus acidophilus und deren verwendung
ES2607988T3 (es) 2005-05-31 2017-04-05 Iams Europe B.V. Bifidobacterias probióticas felinas
BRPI0611493B1 (pt) 2005-05-31 2022-04-05 Alimentary Health Ltd. Lactobacilos probióticos felinos
JP5047190B2 (ja) 2005-12-14 2012-10-10 オクセラ インコーポレイテッド シュウ酸塩関連疾患を治療または予防するための医薬組成物および方法
EP2366402A1 (de) 2005-12-16 2011-09-21 OxThera, Inc., Zusammensetzungen und Verfahren zur Oxalatreduktion
CA2682763A1 (en) * 2007-03-27 2008-10-02 The Procter & Gamble Company Methods and kits for administering probiotics
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CN101606952B (zh) * 2008-06-17 2012-09-19 上海交通大学医学院附属第三人民医院 乳双歧杆菌在制备预防泌尿系统结石药物中的应用
EP2338976B1 (de) 2008-09-30 2017-08-16 Meiji Co., Ltd. Milchsäurebakterium mit hoher oxalsäurezersetzungsfähigkeit
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
ITMI20110791A1 (it) * 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
ITMI20121173A1 (it) * 2012-07-04 2014-01-05 Neupharma Srl Composizioni dietetiche e/o farmaceutiche comprendenti ceppi di lactobacillus e bifidobacterium capaci di degradare gli ossalati e di indurre una risposta immunitaria di tipo anti-infiammatorio
ITMI20130793A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
ITMI20130795A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici e/o bifidobatteri per uso nel trattamento preventivo e/o curativo delle infezioni batteriche e/o delle infiammazioni del tratto urinario e/o della prostata che sono la causa di prostatiti e ipertrofia prostat
JP5765832B2 (ja) * 2013-12-26 2015-08-19 雪印メグミルク株式会社 加齢に伴う代謝異常症の予防・改善・治療剤
WO2016051358A1 (en) * 2014-10-01 2016-04-07 Triphase Pharmaceuticals Pvt. Ltd. Thermo-stable strains, products and methods thereof
ITUB20155752A1 (it) 2015-11-19 2017-05-19 Probiotical Spa Composizione di batteri per uso per attenuare le diminuzioni di prestazione dopo un esercizio fisico che danneggia i muscoli.
CN107868776A (zh) 2016-09-23 2018-04-03 武汉康复得生物科技股份有限公司 糖基化草酸脱羧酶及其制备和应用
US11179426B2 (en) 2016-12-29 2021-11-23 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
BR112021011221A2 (pt) * 2018-12-10 2021-08-31 Novome Biotechnologies, Inc. Métodos e composições para tratar hiperoxalúria
CN113308416B (zh) * 2021-07-20 2023-02-24 四川大学 一株具有抑制肾结石形成能力的植物乳杆菌及其应用
CN115851508B (zh) * 2022-10-13 2024-01-09 山东中科嘉亿生物工程有限公司 一种降草酸、改善肾结石的嗜热链球菌jyst-26及其产品、应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5810520A (ja) * 1981-07-10 1983-01-21 Miyarisan Kk 胆石症の治療薬
ATE172245T1 (de) * 1992-07-06 1998-10-15 Nestle Sa Milchbakterien
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
DE69600525T2 (de) * 1996-12-23 1998-12-10 Sitia Yomo Spa Lyophilisierte, lebende Bakerien enthaltende Nahrungszusammensetzung
EP2033651A1 (de) * 1997-05-23 2009-03-11 OxThera, Inc., Oxalate-abbauende Mikroorganismen oder Oxalate-abbauende Enzyme zur Verhütung der Oxalate-verwandten Krankheiten
RU2139346C1 (ru) * 1999-03-02 1999-10-10 Шендеров Борис Аркадьевич Штамм бактерий lactobacillus plantarum, обладающий способностью снижать уровень оксалата и используемый для приготовления препаратов и продуктов питания для профилактики и лечения гипероксалурии

Also Published As

Publication number Publication date
DK1181027T3 (da) 2004-08-16
AU5101600A (en) 2000-12-18
HUP0201409A3 (en) 2004-10-28
BR0011038A (pt) 2002-02-26
CA2373255A1 (en) 2000-12-07
IL146703A0 (en) 2002-07-25
IT1309427B1 (it) 2002-01-23
US20020061292A1 (en) 2002-05-23
CN1365284A (zh) 2002-08-21
SK16612001A3 (sk) 2002-04-04
PL352014A1 (en) 2003-07-14
WO2000072855A2 (en) 2000-12-07
CZ20014076A3 (cs) 2002-03-13
MXPA01012184A (es) 2003-06-30
ITRM990338A0 (it) 1999-05-28
EE200100618A (et) 2003-02-17
ES2219344T3 (es) 2004-12-01
EP1181027A2 (de) 2002-02-27
BR0011038B1 (pt) 2014-02-18
NZ516020A (en) 2003-06-30
JP2003500451A (ja) 2003-01-07
EA200101262A1 (ru) 2002-04-25
NO20015782D0 (no) 2001-11-27
KR20020019918A (ko) 2002-03-13
DZ3165A1 (fr) 2000-12-07
HUP0201409A2 (en) 2002-08-28
SI1181027T1 (en) 2004-08-31
IL146703A (en) 2010-03-28
IL199437A0 (en) 2011-07-31
IS6150A (is) 2001-11-08
PT1181027E (pt) 2004-09-30
EP1181027B1 (de) 2004-05-06
KR100781703B1 (ko) 2007-12-03
TR200103439T2 (tr) 2002-06-21
HK1048066A1 (en) 2003-03-21
DE60010456D1 (de) 2004-06-09
AU773459B2 (en) 2004-05-27
USRE39585E1 (en) 2007-04-24
WO2000072855A3 (en) 2001-06-28
MA26790A1 (fr) 2004-12-20
IL199437A (en) 2016-10-31
US6562336B2 (en) 2003-05-13
NO20015782L (no) 2002-01-25
HK1048066B (zh) 2008-08-01
ITRM990338A1 (it) 2000-11-28
UA71621C2 (en) 2004-12-15
AR024555A1 (es) 2002-10-16
EA004257B1 (ru) 2004-02-26
CA2373255C (en) 2010-01-19
JP4737836B2 (ja) 2011-08-03
ZA200110504B (en) 2002-09-25
DE60010456T2 (de) 2005-05-12
CN100350919C (zh) 2007-11-28
HU225134B1 (en) 2006-06-28

Similar Documents

Publication Publication Date Title
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
ATE291438T1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
ATE237341T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l- carnitin derivate und ginkgo biloba extrakte
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
DE60107900D1 (de) Pharmazeutische Zusammensetzung und Nahrungsmittel zur Behandlung von Gehirnödem
ATE288279T1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
DE60032817D1 (de) Pharmazeutische zusammensetzung zur behandlung von ulzerationen und/oder erosionen des schleimhautepithels
DE60030593D1 (de) Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien
DE59405654D1 (de) T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen
IL137190A0 (en) Pharmaceutical compositions for the treatment of dyskinesias
IL127102A0 (en) Pharmaceutical compositions for the treatment of dyskinesias
IL122883A0 (en) Pharmaceutical compositions for the treatment of dyskinesias
IT1306143B1 (it) Composizione per la prevenzione ed il trattamento delle alterazionimentali e comportamentali.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1181027

Country of ref document: EP